- ICH GCP
- 米国臨床試験登録
- 臨床試験 NCT07069738
- オリジナルトライアル
左バンドルブランチエリアペーシングと従来の心不全における心臓再同期療法の安全性と有効性 (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jacqueline Beaulieu
- 電話番号:1-800-227-3422
- メール:jacqueline.beaulieu@bsci.com
研究場所
-
-
Alabama
-
Huntsville、Alabama、アメリカ、35801
- 募集
- Heart Center Research, LLC
-
コンタクト:
- John Jennings, Dr.
-
主任研究者:
- John Jennings, Dr.
-
Mobile、Alabama、アメリカ、36608
- 募集
- Mobile Infirmary Medical Center
-
コンタクト:
- Ernest Matthew Quin, Dr.
-
主任研究者:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- 募集
- Mayo Clinic Phoenix
-
コンタクト:
- Mayank Sardana, MD
-
主任研究者:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- 募集
- Arrhythmia Research Group
-
コンタクト:
- Devi Nair, Dr.
-
主任研究者:
- Devi Nair, Dr.
-
-
California
-
La Jolla、California、アメリカ、92037
- 募集
- Scripps Memorial Hospital
-
コンタクト:
- Nicolas Olson, MD
-
主任研究者:
- Nicolas Olson, MD
-
Los Angeles、California、アメリカ、90048
- 募集
- Cedars Sinai Medical Center
-
主任研究者:
- Ashkan Ehdaie, MD
-
コンタクト:
- Ashkan Ehdaie, MD
-
Oakland、California、アメリカ、94609
- 募集
- Alta Bates Summit Medical Center
-
コンタクト:
- Rajan Shah, Dr.
-
主任研究者:
- Rajan Shah, Dr.
-
Santa Monica、California、アメリカ、90404
- 募集
- Pacific Heart Institute
-
コンタクト:
- Stephen Tang, MD
-
主任研究者:
- Stephan Tang, MD
-
Torrance、California、アメリカ、90505
- 募集
- Torrance Medical Center
-
主任研究者:
- Gene Kim, MD
-
コンタクト:
- Gene Kim, MD
-
Ventura、California、アメリカ、93003
- 募集
- Cardiology Associates Medical Group, Inc.
-
コンタクト:
- Jonathan Dukes, Dr.
-
主任研究者:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- 募集
- Washington Hospital Center
-
コンタクト:
- Cyrus Hadadi, MD
-
主任研究者:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota、Florida、アメリカ、34239
- 募集
- Sarasota Memorial Hospital
-
コンタクト:
- Antonio Moretta, Dr.
-
主任研究者:
- Antonio Moretta, Dr.
-
Tampa、Florida、アメリカ、33613
- 募集
- AdventHealth Tampa
-
主任研究者:
- Kenneth Yamamura, MD
-
コンタクト:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30309
- 募集
- Piedmont Hospital
-
コンタクト:
- Kavita Krishnasamy, MD
-
主任研究者:
- Kavita Krishnasamy, MD
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University Hospital
-
コンタクト:
- Anand Shah, MD
-
主任研究者:
- Anand Shah, MD
-
-
Idaho
-
Meridian、Idaho、アメリカ、83642
- 募集
- St. Luke's Idaho Cardiology Associates
-
コンタクト:
- Justice Oranefo, MD
-
主任研究者:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale、Illinois、アメリカ、60521
- 募集
- University of Chicago
-
コンタクト:
- Shrinath Yeshwant, MD
-
主任研究者:
- Shrinath Yeshwant, MD
-
Naperville、Illinois、アメリカ、60540
- 引きこもった
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46250
- 募集
- Community Heart and Vascular Hospital
-
コンタクト:
- Krishna Malineni, MD
-
主任研究者:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa Hospitals and Clinics
-
主任研究者:
- Paari Dominic, MD
-
コンタクト:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40207
- 募集
- Baptist Hospital East Louisville
-
主任研究者:
- Kevin Parrott, MD
-
コンタクト:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River、Massachusetts、アメリカ、02720
- 募集
- Southcoast Physicians Group
-
コンタクト:
- Arnoldas Giedrimas, MD
-
主任研究者:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Hospitals
-
主任研究者:
- Thomas Crawford, MD
-
コンタクト:
- Thomas Crawford, MD
-
Grand Rapids、Michigan、アメリカ、49525
- 募集
- Corewell Health
-
コンタクト:
- Jawad Wassim, MD
-
主任研究者:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth、Minnesota、アメリカ、55805
- 引きこもった
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud、Minnesota、アメリカ、56303
- 引きこもった
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown、New Jersey、アメリカ、07932
- 募集
- Morristown Medical Center
-
コンタクト:
- Michael Katz, MD
-
主任研究者:
- Michael Katz, MD
-
-
New York
-
Albany、New York、アメリカ、12211
- 募集
- Capital Cardiology Associates
-
コンタクト:
- Rizwan Alimohammad, MD
-
主任研究者:
- Rizwan Alimohammad, MD
-
Flushing、New York、アメリカ、11355
- 募集
- New York Hospital Queens
-
コンタクト:
- Seth Goldbarg, Dr.
-
主任研究者:
- Seth Goldbarg, Dr.
-
New York、New York、アメリカ、10021
- 募集
- Weill Cornell Medical University
-
コンタクト:
- Jim Cheung, Dr.
-
主任研究者:
- Jim Cheung, Dr.
-
New York、New York、アメリカ、14621
- 募集
- Rochester General Hospital
-
コンタクト:
- Dmitry Chuprun, MD
-
主任研究者:
- Dmitry Chuprun, MD
-
Syracuse、New York、アメリカ、13057
- 募集
- SUNY-Upstate Medical University
-
コンタクト:
- Jorge Romero, MD
-
主任研究者:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- 募集
- Sanger Heart and Vascular Institute
-
コンタクト:
- Navid Nafissi, MD
-
主任研究者:
- Navid Nafissi, MD
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke University Medical Center
-
コンタクト:
- Daniel Friedman, MD
-
主任研究者:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus、Ohio、アメリカ、43219
- 募集
- Mount Carmel Health System
-
コンタクト:
- Kamel Addo, MD
-
主任研究者:
- Kamel Addo, MD
-
Columbus、Ohio、アメリカ、43214
- 募集
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
コンタクト:
- Anish Amin, MD
-
主任研究者:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Penn Presbyterian Medical Center
-
コンタクト:
- John Bullinga, MD
-
主任研究者:
- John Bullinga, MD
-
Wilkes-Barre、Pennsylvania、アメリカ、18702
- 募集
- Geisinger Wyoming Valley
-
主任研究者:
- Pugazhendhi Vijayaraman, MD
-
コンタクト:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57108
- 募集
- Avera Heart Hospital of South Dakota
-
コンタクト:
- Christopher Stanton, Dr.
-
主任研究者:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37205
- 募集
- St.Thomas Health
-
コンタクト:
- Ricardo Lugo, MD
-
主任研究者:
- Ricardo Lugo, MD
-
-
Texas
-
Plano、Texas、アメリカ、75093
- 募集
- Heart Hospital Baylor Plano
-
コンタクト:
- Mustafa Dohadwala, MD
-
主任研究者:
- Mustafa Dohadwala, MD
-
Tyler、Texas、アメリカ、75701
- 募集
- Christus Trinity Mother Frances Health System
-
コンタクト:
- Stanislov Weiner, Dr.
-
主任研究者:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- 募集
- University of Virginia Medical Center
-
主任研究者:
- Pamela Mason, MD
-
コンタクト:
- Pamela Mason, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
実験的:LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
時間枠:Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
時間枠:12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Win ratio composite assessment
時間枠:Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
時間枠:Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
時間枠:12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。